Back to top
more

SYNTHORX INC. - COMMON STOCK (THOR)

(Delayed Data from NSDQ)

$17.04 USD

17.04
75,156

+0.23 (1.37%)

Updated May 3, 2019 04:00 PM ET

After-Market: $16.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Can Winnebago Replicate This Year's Stellar Show in 2020?

Winnebago (WGO) looks well poised to maintain this year's momentum in the New Year, courtesy of its leadership position in the industry, game-changing acquisitions and solid financials.

Sweta Killa headshot

Biotech Leading in Q4: Best ETFs & Stocks

We highlight five biotech ETFs and stocks that are leading the market in Q4.

Moving Average Crossover Alert: Synthorx

Synthorx, Inc. (THOR) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Neena Mishra headshot

Why Biotech ETFs are Surging to New Highs

increasing M&A deals and cutting edge therapies are driving biotech ETFs higher

Sweta Killa headshot

Biotech ETFs Hit New Highs on Deal Activities

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

Company News for Dec 10, 2019

Companies in the news are: ARQL, THOR, CGC, FATE

Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research

Sanofi (SNY) to prioritize key growth drivers, improve operating efficiencies and generate cost savings. The company discontinues R&D activities in diabetes and cardiovascular segments.

Kinjel Shah headshot

Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms

Merck offers to buy ArQule for $2.7 billion while Sanofi signs a definitive deal to purchase Synthorx for $2.5 billion.

Week Begins with Biotech Mergers

Week Begins with Biotech Mergers

Mark Vickery headshot

Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More

Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).

Sanofi to Buy Synthorx for $2.5B to Boost Cancer Portfolio

Sanofi (SNY) offers to buy Synthorx (THOR) for $2.5 billion. The deal will add Synthorx's lead pipeline asset, THOR-707 to Sanofi's oncology portfolio.

Will Synthorx Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Synthorx.

Synthorx's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Synthorx.